Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis

Psoriasis is an immune-mediated skin disease with various presentations. HIV infection affects the immune system and aggravates psoriasis lesions. Therefore, psoriasis management in HIV patients poses a great challenge for dermatologists. In this report, 2 HIV patients with erythrodermic psoriasis r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pangilinan, Mary Catherine G., Sermswan, Peerada, Asawanonda, Pravit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506271/
https://www.ncbi.nlm.nih.gov/pubmed/32999648
http://dx.doi.org/10.1159/000508781
_version_ 1783584985492488192
author Pangilinan, Mary Catherine G.
Sermswan, Peerada
Asawanonda, Pravit
author_facet Pangilinan, Mary Catherine G.
Sermswan, Peerada
Asawanonda, Pravit
author_sort Pangilinan, Mary Catherine G.
collection PubMed
description Psoriasis is an immune-mediated skin disease with various presentations. HIV infection affects the immune system and aggravates psoriasis lesions. Therefore, psoriasis management in HIV patients poses a great challenge for dermatologists. In this report, 2 HIV patients with erythrodermic psoriasis received anti-IL-17 and experienced significant clearance of lesions. No recurrence or opportunistic infection was noted. In conclusion, anti-IL-17 monoclonal antibodies are an effective and promising treatment option for HIV-infected patients with psoriasis.
format Online
Article
Text
id pubmed-7506271
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-75062712020-09-29 Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis Pangilinan, Mary Catherine G. Sermswan, Peerada Asawanonda, Pravit Case Rep Dermatol Case Series Psoriasis is an immune-mediated skin disease with various presentations. HIV infection affects the immune system and aggravates psoriasis lesions. Therefore, psoriasis management in HIV patients poses a great challenge for dermatologists. In this report, 2 HIV patients with erythrodermic psoriasis received anti-IL-17 and experienced significant clearance of lesions. No recurrence or opportunistic infection was noted. In conclusion, anti-IL-17 monoclonal antibodies are an effective and promising treatment option for HIV-infected patients with psoriasis. S. Karger AG 2020-08-12 /pmc/articles/PMC7506271/ /pubmed/32999648 http://dx.doi.org/10.1159/000508781 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Series
Pangilinan, Mary Catherine G.
Sermswan, Peerada
Asawanonda, Pravit
Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
title Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
title_full Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
title_fullStr Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
title_full_unstemmed Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
title_short Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
title_sort use of anti-il-17 monoclonal antibodies in hiv patients with erythrodermic psoriasis
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506271/
https://www.ncbi.nlm.nih.gov/pubmed/32999648
http://dx.doi.org/10.1159/000508781
work_keys_str_mv AT pangilinanmarycatherineg useofantiil17monoclonalantibodiesinhivpatientswitherythrodermicpsoriasis
AT sermswanpeerada useofantiil17monoclonalantibodiesinhivpatientswitherythrodermicpsoriasis
AT asawanondapravit useofantiil17monoclonalantibodiesinhivpatientswitherythrodermicpsoriasis

Ejemplares similares